Sartorius Stedim Biotech (SSB) reports EPS of 0.58 euros for the first three months of 2024, compared with 1.21 euros a year earlier, and recurring EBITDA down 13.2% to 191 million euros, giving a margin of 28.6% versus 30.3% for the same period in 2023.

The supplier of products and services to the pharmaceutical industry posted sales of €667 million, down 6.7% at constant exchange rates, but booked orders of €676 million, up 13.9% at constant exchange rates.

For the current year, SSB continues to anticipate a gradual recovery in business as the quarters go by, and expects sales growth "in the mid- to high-single digits", as well as a current EBITDA margin in excess of 30%.

Copyright (c) 2024 CercleFinance.com. All rights reserved.